Is CBL p.Pro495Leu (c.1484C>T) pathogenic?

CBL p.Pro495Leu (c.1484C>T) is classified Uncertain significance in CBL (ClinVar, Multiple submitters, 5 submitters; last evaluated 2025-10-28). AlphaMissense: likely pathogenic (0.8932); Very rare (popmax 0.00549%, sas); Associated with RASopathy.

What condition is associated with CBL p.Pro495Leu (c.1484C>T)?

CBL p.Pro495Leu (c.1484C>T) is associated with RASopathy, juvenile myelomonocytic leukemia, CBL-related disorder (ClinVar).

How common is CBL p.Pro495Leu (c.1484C>T) in the general population?

CBL p.Pro495Leu (c.1484C>T) is very rare (popmax 0.00549%, sas) (gnomAD).

What do computational predictors say about CBL p.Pro495Leu (c.1484C>T)?

AlphaMissense predicts likely pathogenic (score 0.8932) — an in-silico prediction, not a clinical call.

CBL p.Pro495Leu

c.1484C>T · rs373989524 · VCV378875

Uncertain significance Multiple submitters

Classification

Uncertain significance

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 5 submitters

AlphaMissense

likely pathogenic

0.8932 · ACMG-weighted

gnomAD v4.1

Rare

very rare (popmax 0.00549%, sas)

Missense predictors

2/3 damaging

AlphaMissense, REVEL, SaProt

Conditions

RASopathy

Computational evidence

Protein change
AlphaMissense	0.8932	likely pathogenic
REVEL	0.715	pathogenic-leaning
SaProt	LLR -9.32	tolerated
⇒ AlphaMissense and REVEL call this damaging; SaProt does not.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 7.6	GERP 2, phastCons 1
Regional constraint	o/e 1.05	unconstrained · MANE · 22 kb · p 0.19 · regional, not allelic
Overall
CADD	29.5	PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.00549% South Asian · 5/91,084 alleles

Filtering AF 0.0021% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.00136%

Overall 0.00223% 36/1,614,066 alleles · very rare

Ancestry group	Frequency	1 in
South Asiangrpmax	0.00549%	18,217
East Asian	0.00445%	22,451
European (non-Finnish)	0.00229%	43,705
Admixed American	0.00167%	60,006
Finnishnot grpmax-eligible	0.00156%	64,036

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: CBL
Protein: p.Pro495Leu
Coding: c.1484C>T
MANE Select: NM_005188
dbSNP: rs373989524
Type: single nucleotide variant
Location: chr11:119285021 (GRCh38)
Gene constraint: LOEUF 0.622 · pLI <0.01 · ClinGen HI 0/3 (gnomAD)
Structure: AlphaFold pLDDT 64.27 · 34 PDB
Residue 495: the 'required for ubiquitination of spred2' region; the 'disordered' region

Full CBL gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

RASopathy — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: juvenile myelomonocytic leukemia CBL-related disorder

Similar variants

CBL p.Pro495Gln Uncertain significance ★ ⚠ same residue
CBL p.Pro495fs Uncertain significance ★ same residue
CBL p.Pro495= Benign ★ same residue
CBL c.1096-1G>C Pathogenic/Likely pathogenic ★★ same condition
CBL c.1096-1G>T Pathogenic ★★ same condition
CBL c.1096-2A>T Pathogenic ★★ same condition
CBL c.1228-2A>G Pathogenic/Likely pathogenic ★★ same condition
CBL p.Arg420Gln Pathogenic/Likely pathogenic ★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/cbl-p-pro495leu (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown